Craniopharyngioma clinical trials at UCSF
2 research studies open to eligible people
Craniopharyngioma refers to a growth near the brain that can create major health issues. UCSF is testing FOG-001 to ensure it is safe for people with advanced cancer. UCSF is also investigating if Tovorafenib can treat craniopharyngioma in younger individuals.
FOG-001 in Locally Advanced or Metastatic Solid Tumors
open to eligible people ages 18 years and up
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.
San Francisco, California and other locations
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
open to eligible people ages 1-39
The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
San Francisco, California and other locations
Our lead scientists for Craniopharyngioma research studies include Sabine Mueller, MD, PhD, MAS.
Last updated: